{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:04:39Z","timestamp":1793505879409,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan and from the Ministry of Education, Culture, Sports, Science and Technology of Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thrombotic complications and coagulopathy frequently occur in COVID-19. However, the characteristics of COVID-19-associated coagulopathy (CAC) are distinct from those seen with bacterial sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation (DIC), with CAC usually showing increased D-dimer and fibrinogen levels but initially minimal abnormalities in prothrombin time and platelet count. Venous thromboembolism and arterial thrombosis are more frequent in CAC compared to SIC\/DIC. Clinical and laboratory features of CAC overlap somewhat with a hemophagocytic syndrome, antiphospholipid syndrome, and thrombotic microangiopathy. We summarize the key characteristics of representative coagulopathies, discussing similarities and differences so as to define the unique character of CAC.<\/jats:p>","DOI":"10.1186\/s13054-020-03077-0","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T07:02:59Z","timestamp":1592463779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":418,"title":["The unique characteristics of COVID-19 coagulopathy"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-4088","authenticated-orcid":false,"given":"Toshiaki","family":"Iba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marie","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore E.","family":"Warkentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"3077_CR1","doi-asserted-by":"publisher","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.2648.","DOI":"10.1001\/jama.2020.2648"},{"issue":"20","key":"3077_CR2","first-page":"30145","volume":"S2352-3026","author":"M Levi","year":"2020","unstructured":"Levi M, Thachil J, Iba T, Levy J. Coagulation abnormalities and thrombosis in patients with COVID-19 infection. Lancet Haematol. 2020;S2352-3026(20):30145\u20139.","journal-title":"Lancet Haematol"},{"issue":"18","key":"3077_CR3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"L Wei","year":"2020","unstructured":"Wei L, Liu Y, Hu YH, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708\u201320.","journal-title":"N Engl J Med"},{"key":"3077_CR4","doi-asserted-by":"publisher","unstructured":"Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020. https:\/\/doi.org\/10.1111\/jth.14768.","DOI":"10.1111\/jth.14768"},{"issue":"5","key":"3077_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/jth.14810","volume":"18","author":"J Thachil","year":"2020","unstructured":"Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023\u20136.","journal-title":"J Thromb Haemost"},{"key":"3077_CR6","doi-asserted-by":"publisher","unstructured":"Wichmann D, Sperhake JP, L\u00fctgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/M20-2003.","DOI":"10.7326\/M20-2003"},{"key":"3077_CR7","doi-asserted-by":"publisher","unstructured":"Mehra MR, Desai SS, Kuy S, et al. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2007621.","DOI":"10.1056\/NEJMoa2007621"},{"key":"3077_CR8","doi-asserted-by":"publisher","unstructured":"Tang N, Bai H, Chen X, et al. Anticoagulanttreatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. https:\/\/doi.org\/10.1111\/jth.14817.","DOI":"10.1111\/jth.14817"},{"key":"3077_CR9","doi-asserted-by":"publisher","unstructured":"Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.001.","DOI":"10.1016\/j.jacc.2020.05.001"},{"issue":"2","key":"3077_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/jth.13911","volume":"16","author":"T Iba","year":"2018","unstructured":"Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 2018;16(2):231\u201341.","journal-title":"J Thromb Haemost"},{"key":"3077_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12959-019-0198-4","volume":"17","author":"JC Chang","year":"2019","unstructured":"Chang JC. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. Thromb J. 2019;17:10.","journal-title":"Thromb J"},{"key":"3077_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/cc13983","volume":"18","author":"T Iba","year":"2014","unstructured":"Iba T, Miki T, Hashiguchi N, et al. Is the neutrophil a \u2018prima donna\u2019 in the procoagulant process during sepsis? Crit Care. 2014;18:230.","journal-title":"Crit Care"},{"key":"3077_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.blre.2015.12.004","volume":"30","author":"PC Liaw","year":"2016","unstructured":"Liaw PC, Ito T, Iba T, et al. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Rev. 2016;30:257\u201361.","journal-title":"Blood Rev"},{"key":"3077_CR14","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1038\/s41598-018-22156-5","volume":"8","author":"Y Wang","year":"2018","unstructured":"Wang Y, Luo L, Braun O\u00d6, et al. Neutrophil extracellular trap-microparticle complexes enhance thrombin generation via the intrinsic pathway of coagulation in mice. Sci Rep. 2018;8:4020.","journal-title":"Sci Rep"},{"key":"3077_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1055\/s-2001-18866","volume":"27","author":"B \u00d8sterud","year":"2001","unstructured":"\u00d8sterud B, Bj\u00f8rklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27:605\u201317.","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"3077_CR16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1097\/ALN.0000000000003122","volume":"132","author":"T Iba","year":"2020","unstructured":"Iba T, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Anesthesiology. 2020;132(5):1238\u201345.","journal-title":"Anesthesiology."},{"issue":"11","key":"3077_CR17","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1111\/jth.14578","volume":"17","author":"T Iba","year":"2019","unstructured":"Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989\u201394.","journal-title":"J Thromb Haemost"},{"key":"3077_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40560-015-0075-6","volume":"3","author":"S Madoiwa","year":"2015","unstructured":"Madoiwa S. Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC. J Intensive Care. 2015;3:8.","journal-title":"J Intensive Care"},{"issue":"1","key":"3077_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13054-020-02895-6","volume":"24","author":"D Wang","year":"2020","unstructured":"Wang D, Yin Y, Hu C, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan. China Crit Care. 2020;24(1):188.","journal-title":"China Crit Care"},{"key":"3077_CR20","doi-asserted-by":"publisher","unstructured":"Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020:1\u201310. https:\/\/doi.org\/10.1007\/s00134-020-06062-x.","DOI":"10.1007\/s00134-020-06062-x"},{"issue":"4","key":"3077_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.thromres.2007.12.021","volume":"122","author":"M Yang","year":"2008","unstructured":"Yang M, Ng MH, Li CK, et al. Thrombopoietin levels increased in patients with severe acute respiratory syndrome. Thromb Res. 2008;122(4):473\u20137.","journal-title":"Thromb Res"},{"issue":"4","key":"3077_CR22","doi-asserted-by":"publisher","first-page":"e00271","DOI":"10.1128\/mBio.00271-13","volume":"4","author":"LE Gralinski","year":"2013","unstructured":"Gralinski LE, Bankhead A 3rd, Jeng S, et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio. 2013;4(4):e00271\u201313.","journal-title":"mBio"},{"issue":"10234","key":"3077_CR23","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417\u20138.","journal-title":"Lancet"},{"issue":"1","key":"3077_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1124\/jpet.107.130609","volume":"325","author":"MA Richardson","year":"2008","unstructured":"Richardson MA, Gupta A, O'Brien LA, et al. Treatment of sepsis-induced acquired protein C deficiency reverses angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response. J Pharmacol Exp Ther. 2008;325(1):17\u201326.","journal-title":"J Pharmacol Exp Ther"},{"key":"3077_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bcmd.2016.10.023","volume":"64","author":"S Ramachandra","year":"2017","unstructured":"Ramachandra S, Zaidi F, Aggarwal A, Gera R. Recent advances in diagnostic and therapeutic guidelines for primary and secondary hemophagocytic lymphohistiocytosis. Blood Cells Mol Dis. 2017;64:53\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"3077_CR26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124\u201331.","journal-title":"Pediatr Blood Cancer"},{"issue":"10229","key":"3077_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033\u20134.","journal-title":"Lancet"},{"issue":"6490","key":"3077_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473\u20134.","journal-title":"Science"},{"issue":"5","key":"3077_CR29","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"Q Ruan","year":"2020","unstructured":"Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Intensive Care Med. 2020;46(5):846\u20138.","journal-title":"China Intensive Care Med"},{"key":"3077_CR30","first-page":"726","volume":"10","author":"RL Kleynberg","year":"2012","unstructured":"Kleynberg RL, Schiller GJ. Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol. 2012;10:726\u201332.","journal-title":"Clin Adv Hematol Oncol"},{"key":"3077_CR31","doi-asserted-by":"publisher","unstructured":"Dimopoulos G, de Mast Q, Markou N, et al. Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020. https:\/\/doi.org\/10.1016\/j.chom.2020.05.007.","DOI":"10.1016\/j.chom.2020.05.007"},{"key":"3077_CR32","doi-asserted-by":"crossref","unstructured":"Iba T, Levy J, Levi M, et al. Coagulopathy of COVID-19. Crit Care Med 2020 In press.","DOI":"10.1111\/jth.14975"},{"issue":"20","key":"3077_CR33","doi-asserted-by":"publisher","first-page":"30764","DOI":"10.1016\/j.chest.2020.04.024","volume":"S0012-3692","author":"J Radbel","year":"2020","unstructured":"Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. Chest. 2020;S0012-3692(20):30764\u20139. https:\/\/doi.org\/10.1016\/j.chest.2020.04.024.","journal-title":"Chest"},{"issue":"5","key":"3077_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","volume":"39","author":"R Channappanavar","year":"2017","unstructured":"Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529\u201339.","journal-title":"Semin Immunopathol"},{"issue":"17","key":"3077_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2007575","volume":"382","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382(17):e38.","journal-title":"N Engl J Med"},{"key":"3077_CR36","doi-asserted-by":"publisher","unstructured":"Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMc2013656.","DOI":"10.1056\/NEJMc2013656"},{"key":"3077_CR37","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1136\/annrheumdis-2016-211001","volume":"76","author":"N Groot","year":"2017","unstructured":"Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 2017;76:1637\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3077_CR38","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1191\/0961203303lu413oa","volume":"12","author":"FJ Wiedermann","year":"2003","unstructured":"Wiedermann FJ, Lederer W, Mayr AJ, et al. Prospective observational study of antiphospholipid antibodies in acute lung injury and acute respiratory distress syndrome: comparison with catastrophic antiphospholipid syndrome. Lupus. 2003;12(6):462\u20137.","journal-title":"Lupus"},{"key":"3077_CR39","doi-asserted-by":"crossref","first-page":"254","DOI":"10.23736\/S0031-0808.17.03324-9","volume":"59","author":"G Espinosa","year":"2017","unstructured":"Espinosa G, Rodr\u00edguez-Pint\u00f3 I, Cervera R. Catastrophic antiphospholipid syndrome: an update. Panminerva Med. 2017;59:254\u201368.","journal-title":"Panminerva Med"},{"key":"3077_CR40","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","volume":"378","author":"D Garcia","year":"2018","unstructured":"Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378:2010\u201321.","journal-title":"N Engl J Med"},{"key":"3077_CR41","doi-asserted-by":"publisher","unstructured":"Zhou X, Li Y, Yang Q. Antiplatelet therapy following percutaneous coronary intervention in patients complicated by COVID-19: implications from clinical features to pathological findings. Circulation. 2020. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046988.","DOI":"10.1161\/CIRCULATIONAHA.120.046988"},{"issue":"16","key":"3077_CR42","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582\u20139.","journal-title":"JAMA"},{"key":"3077_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.thromres.2020.04.014","volume":"190","author":"R Escher","year":"2020","unstructured":"Escher R, Breakey N, L\u00e4mmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62.","journal-title":"Thromb Res"},{"key":"3077_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12959-018-0168-2","volume":"16","author":"H Wada","year":"2018","unstructured":"Wada H, Matsumoto T, Suzuki K, et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;16:14.","journal-title":"Thromb J"},{"key":"3077_CR45","doi-asserted-by":"publisher","unstructured":"Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. 2020. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047419.","DOI":"10.1161\/CIRCULATIONAHA.120.047419"},{"issue":"3","key":"3077_CR46","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s12288-018-1058-2","volume":"35","author":"N Tadkalkar","year":"2019","unstructured":"Tadkalkar N, Prasad S, Gangodkar S, et al. Dengue virus NS1 exposure affects von Willebrand factor profile and platelet adhesion properties of cultured vascular endothelial cells. Indian J Hematol Blood Transfus. 2019;35(3):502\u20136.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"4","key":"3077_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.thromres.2005.01.005","volume":"116","author":"V Rold\u00e1n","year":"2005","unstructured":"Rold\u00e1n V, Mar\u00edn F, Garc\u00eda-Herola A, Lip GY. Correlation of plasma von Willebrand factor levels, an index of endothelial damage\/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res. 2005;116(4):321\u20135.","journal-title":"Thromb Res"},{"key":"3077_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","volume":"158","author":"M Scully","year":"2012","unstructured":"Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323\u201335.","journal-title":"Br J Haematol"},{"key":"3077_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.chest.2017.03.055","volume":"152","author":"E Azoulay","year":"2017","unstructured":"Azoulay E, Knoebl P, Garnacho-Montero J, et al. Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest. 2017;152:424\u201334.","journal-title":"Chest"},{"key":"3077_CR50","doi-asserted-by":"publisher","unstructured":"Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: success doesn\u2019t come easily. Br J Haematol. 2020. https:\/\/doi.org\/10.1111\/bjh.","DOI":"10.1111\/bjh"},{"issue":"1","key":"3077_CR51","first-page":"77","volume":"7","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Zhao G, Song N, et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):77.","journal-title":"Emerg Microbes Infect"},{"key":"3077_CR52","doi-asserted-by":"crossref","unstructured":"Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020: S1931-5244(20)30070\u20130.","DOI":"10.1016\/j.trsl.2020.04.007"},{"key":"3077_CR53","doi-asserted-by":"publisher","unstructured":"Moores G, Warkentin TE, Mohammed AM, et al. Spontaneous heparin-induced thrombocytopenia presenting as cerebral venous sinus thrombosis. Neurol Clin Pract. 2020. https:\/\/doi.org\/10.1212\/CPJ.0000000000000805.","DOI":"10.1212\/CPJ.0000000000000805"},{"key":"3077_CR54","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","volume":"106","author":"N Martel","year":"2005","unstructured":"Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710\u20135.","journal-title":"Blood"},{"key":"3077_CR55","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1160\/TH16-06-0435","volume":"116","author":"TE Warkentin","year":"2016","unstructured":"Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost. 2016;116:813\u201322.","journal-title":"Thromb Haemost"},{"key":"3077_CR56","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/jth.13813","volume":"15","author":"A Greinacher","year":"2017","unstructured":"Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017;15:2099\u2013114.","journal-title":"J Thromb Haemost"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-03077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-020-03077-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-020-03077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T02:54:56Z","timestamp":1667012096000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-020-03077-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3077"],"URL":"https:\/\/doi.org\/10.1186\/s13054-020-03077-0","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TI has received a research grant from the Japan Blood Products Organization and JIMRO. JHL serves on the Steering Committees for Boehringer-Ingelheim, CSL Behring, Instrumentation Laboratories, Octapharma, and Leading Biosciences. JMC receives personal fees from the Bristol-Meyer Squibb, Abbott, Portola, and research funding to the institution from CSL Behring. TEW reports receiving consulting fees from the Aspen Global, Bayer, CSL Behring, Ergomed Instrumentation Laboratory, and Octapharma; research support from the Instrumentation Laboratory; royalties from the Informa (Taylor & Francis); and consulting fees related to medical-legal consulting and testimony. ML has received grants and has participated in advisory boards of the NovoNordisk, Eli Lilly, Asahi Kasei Pharmaceuticals America and Johnson & Johnson. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"360"}}